|
The VAXON-Biotech's IP portfolio is composed of eight patent families. Three of them are proprietary of INSERM/IGR for which VAXON-Biotech obtained an exclusive and worldwide license, while the remaining five families are VAXON-Biotech's proprietary.
Five of these patents have already been granted in Europe, four in US, one in Japan one in China and one in Canada.
Several scientific publications in peer review journals, with high impact factor, support the therapeutic potential of the "Optimized cryptic peptides" technology:
Vx-001 publications:
J. Immunol., 2002, 168: 5900-5906
J.Clin. Invest. 2004, 113: 425-433
Vaccine, 2006, 24: 1880-1888
Oncology, 2006, 70: 306-314
J. Clin. Oncol., 2007, 25: 2727-2734
Cancer Immunol. Immunother., 2012, 61: 157-68
Ann. Oncol., 2012, 23: 442-449
J. Immunother., 2011, 34:641-50
Vx-006 publications:
J.Immunol., 2002, 168: 5900-5906
J. Immunol., 2002, 169: 575-580
Vaccine, 2006, 24: 2102-2109
|
top of page
home .
contact .
terms of use .
sitemap .
Contact & directions